In addition, since DHTS-I differentially controls the HuR-mediated expression of TRIM21 (a pro-oncogenic factor) and p53 (an anti-oncogenic factor), it has the potential of being developed as a therapeutic to treat autoimmune disorders and cancers. Here, ELAVL1 is linked to cancer.